Coherus avoided having to conduct a study in which patients switched back and forth between Cimerli and the reference product Lucentis • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
